Development and validation of an RNA-based biomarker to determine biological response

The Belgian biotech company argenx is currently running a clinical trial of ARGX-110, a first-in-class SIMPLE antibody targeting CD70, an immune checkpoint target involved in hematological malignancies, solid tumors and severe autoimmune diseases.

To determine the biological response to ARGX-110, Biogazelle has developed and validated an RT-qPCR-based test for accurate and sensitive CD70 mRNA measurement on whole blood. Measurement of this RNA biomarker on samples coming from their clinical study (currently in phase 2a) is also performed at Biogazelle.

"argenx is a clinical stage human monoclonal antibody therapeutics company. Our business model relies on outsourcing and Biogazelle is our outsourcing partner to set-up and perform mRNA analyses in both the pre-clinical and clinical phases of our running projects.
We selected Biogazelle because they have a decade of experience in real-time PCR experiment design, assay development and data-analysis. The scientific support by Biogazelle's project manager has been outstanding. I would recommend Biogazelle as a solid service provider with a highly professional and personal approach."

- dr. Karen Silence, Project Manager ARGX-110, argenx, Belgium